Press Releases

NEWS RELEASE 12.10.2024

AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDEND

NEWS RELEASE 12.07.2024

BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

NEWS RELEASE 12.05.2024

AMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINA

NEWS RELEASE 12.02.2024

AMGEN TO PRESENT AT CITI'S 2024 GLOBAL HEALTHCARE CONFERENCE

NEWS RELEASE 11.29.2024

AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE

NEWS RELEASE 11.26.2024

AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY

NEWS RELEASE 11.26.2024

AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM

NEWS RELEASE 11.20.2024

AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT

NEWS RELEASE 11.14.2024

AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024

NEWS RELEASE 11.13.2024

AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA

NEWS RELEASE 11.08.2024

AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE

NEWS RELEASE 11.08.2024

TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

NEWS RELEASE 10.30.2024

AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS

NEWS RELEASE 10.25.2024

AMGEN ANNOUNCES 2024 FOURTH QUARTER DIVIDEND

NEWS RELEASE 10.24.2024

AMGEN ANNOUNCES WEBCAST OF 2024 THIRD QUARTER FINANCIAL RESULTS

NEWS RELEASE 10.15.2024

AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024

NEWS RELEASE 10.01.2024

LA LA ANTHONY PARTNERS WITH AMGEN TO SHARE CANDID, BEHIND-THE-SCENES LOOK AT HOW PLAQUE PSORIASIS AFFECTS HER LIFE

NEWS RELEASE 09.24.2024

TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE

NEWS RELEASE 09.23.2024

AMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASE

NEWS RELEASE 09.13.2024

AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024

NEWS RELEASE 09.09.2024

AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024

NEWS RELEASE 08.30.2024

AMGEN TO PRESENT AT THE 2024 WELLS FARGO HEALTHCARE CONFERENCE

NEWS RELEASE 08.29.2024

AMGEN TO PRESENT AT THE MORGAN STANLEY 22ND ANNUAL GLOBAL HEALTHCARE CONFERENCE

NEWS RELEASE 08.20.2024

OTEZLA® (APREMILAST) NOW AVAILABLE IN THE U.S. FOR MODERATE TO SEVERE PEDIATRIC PLAQUE PSORIASIS

NEWS RELEASE 08.06.2024

AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

NEWS RELEASE 08.02.2024

AMGEN ANNOUNCES 2024 THIRD QUARTER DIVIDEND

NEWS RELEASE 08.01.2024

AMGEN ANNOUNCES WEBCAST OF 2024 SECOND QUARTER FINANCIAL RESULTS

NEWS RELEASE 06.14.2024

FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE

NEWS RELEASE 06.12.2024

AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024

NEWS RELEASE 06.05.2024

AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

NEWS RELEASE 06.05.2024

AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD)

NEWS RELEASE 06.03.2024

AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE

NEWS RELEASE 05.28.2024

AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024

NEWS RELEASE 05.19.2024

NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD

NEWS RELEASE 05.16.2024

FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

NEWS RELEASE 05.15.2024

AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024

NEWS RELEASE 05.09.2024

AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE

NEWS RELEASE 05.02.2024

AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

NEWS RELEASE 05.01.2024

AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024

NEWS RELEASE 04.29.2024

AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS

NEWS RELEASE 04.26.2024

AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY

NEWS RELEASE 04.16.2024

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

NEWS RELEASE 03.09.2024

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024

NEWS RELEASE 03.06.2024

AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND

NEWS RELEASE 02.29.2024

AMGEN TO PRESENT AT THE 44TH ANNUAL TD COWEN HEALTH CARE CONFERENCE

NEWS RELEASE 02.26.2024

AMGEN OPENS STATE-OF-THE-ART BIOMANUFACTURING SITE IN CENTRAL OHIO

NEWS RELEASE 02.19.2024

AMGEN TO HOST CONFERENCE CALL ON RARE DISEASE

NEWS RELEASE 02.09.2024

AMGEN TO PRESENT AT THE 34TH ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE

NEWS RELEASE 02.06.2024

AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS

NEWS RELEASE 02.01.2024

AMGEN ANNOUNCES WEBCAST OF 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

NEWS RELEASE 01.03.2024

AMGEN TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Earnings